Kancera Past Earnings Performance
Past criteria checks 0/6
Kancera's earnings have been declining at an average annual rate of -11.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 96.1% per year.
Key information
-11.2%
Earnings growth rate
23.1%
EPS growth rate
Biotechs Industry Growth | 0.7% |
Revenue growth rate | -96.1% |
Return on equity | -63.9% |
Net Margin | n/a |
Next Earnings Update | 15 Nov 2024 |
Recent past performance updates
Recent updates
Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth
Aug 13We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully
Dec 06Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?
Jul 19Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth
Mar 08We Think Kancera (STO:KAN) Can Afford To Drive Business Growth
Jun 29We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely
Mar 08Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation
Aug 02We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate
Apr 06Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation
Dec 21Revenue & Expenses Breakdown
How Kancera makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -53 | 7 | 48 |
31 Mar 24 | 0 | -60 | 8 | 54 |
31 Dec 23 | 0 | -65 | 8 | 58 |
30 Sep 23 | 0 | -60 | 8 | 53 |
30 Jun 23 | 0 | -61 | 9 | 52 |
31 Mar 23 | 0 | -58 | 8 | 50 |
31 Dec 22 | 0 | -52 | 7 | 46 |
30 Sep 22 | 0 | -51 | 6 | 47 |
30 Jun 22 | 0 | -52 | 4 | 49 |
31 Mar 22 | 0 | -49 | 5 | 45 |
31 Dec 21 | 0 | -46 | 4 | 43 |
30 Sep 21 | 0 | -45 | 6 | 41 |
30 Jun 21 | 0 | -44 | 6 | 39 |
31 Mar 21 | 0 | -38 | 5 | 38 |
31 Dec 20 | 0 | -40 | 6 | 39 |
30 Sep 20 | 0 | -35 | 4 | 35 |
30 Jun 20 | 0 | -34 | 4 | 34 |
31 Mar 20 | 0 | -40 | 8 | 34 |
31 Dec 19 | 3 | -36 | 7 | 35 |
30 Sep 19 | 4 | -41 | 8 | 41 |
30 Jun 19 | 3 | -44 | 8 | 45 |
31 Mar 19 | 3 | -41 | 6 | 44 |
31 Dec 18 | 0 | -46 | 5 | 45 |
30 Sep 18 | 0 | -46 | 4 | 47 |
30 Jun 18 | 0 | -52 | 5 | 51 |
31 Mar 18 | 0 | -59 | 5 | 59 |
31 Dec 17 | 0 | -56 | 5 | 56 |
30 Sep 17 | 0 | -51 | 5 | 46 |
30 Jun 17 | 0 | -39 | 4 | 36 |
31 Mar 17 | 0 | -27 | 4 | 23 |
31 Dec 16 | 0 | -22 | 3 | 19 |
30 Sep 16 | 0 | -22 | 5 | 22 |
30 Jun 16 | 0 | -20 | 5 | 20 |
31 Mar 16 | 0 | -20 | 5 | 20 |
31 Dec 15 | 0 | -20 | 5 | 20 |
30 Sep 15 | 0 | -19 | 3 | 16 |
30 Jun 15 | 0 | -18 | 3 | 16 |
31 Mar 15 | 0 | -17 | 3 | 14 |
31 Dec 14 | 0 | -16 | 3 | 14 |
30 Sep 14 | 2 | -13 | 3 | 12 |
30 Jun 14 | 2 | -13 | 3 | 11 |
31 Mar 14 | 2 | -12 | 4 | 10 |
31 Dec 13 | 2 | -7 | 4 | 8 |
Quality Earnings: KAN is currently unprofitable.
Growing Profit Margin: KAN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KAN is unprofitable, and losses have increased over the past 5 years at a rate of 11.2% per year.
Accelerating Growth: Unable to compare KAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KAN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Return on Equity
High ROE: KAN has a negative Return on Equity (-63.93%), as it is currently unprofitable.